Literature DB >> 32091909

Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.

Yu Sakurai1, Wataru Mizumura1, Kenichiro Ito2, Kazuhiro Iwasaki3, Takayuki Katoh2, Yuki Goto2, Hiroaki Suga2, Hideyoshi Harashima1.   

Abstract

Peptide modification is a popular strategy for developing an active targeting lipid nanoparticle (LNP). In modifying the surface of an LNP with a peptide, the sequence and structure of the peptide strongly affects the formation of the LNP. Specifically, a peptide with a high hydrophobicity can induce coarsening and aggregation of the LNP. In an attempt to prevent this from occurring, we incorporated monoacyl and diacyl group-conjugated poly(ethylene glycol) (PEG) into a LNP. We previously developed an original LNP, a multifunctional envelope type nanodevice (MEND) modified with an Epi-1 peptide, a ligand with a high affinity for the epithelial cell adhesion molecule (EpCAM). Using this peptide-modified MEND, the efficiency of delivery of a small interfering RNA (siRNA) encapsulated in the MEND was significantly improved. Although increasing the ratio of modification enhanced cellular uptake, the increase also induced aggregation of the LNP, particularly in the case of a large scale preparation. Our results indicate that a monoacyl PEG-lipid can prevent aggregation, even when the LNP is modified with higher molar ratios of peptide, but that this also results in a decrease in delivery efficiency. Moreover, the Epi-1-modified MEND exhibited a strong silencing effect in an ovarian cancer peritoneal dissemination model. Our results suggest that the simple incorporation of a monoacyl derivative into the PEG-lipid resulted in the formation of a peptide-modified LNP with improved characteristics.

Entities:  

Keywords:  EpCAM; active targeting; intraperitoneal injection; lipid nanoparticle; ovarian cancer; siRNA

Mesh:

Substances:

Year:  2020        PMID: 32091909     DOI: 10.1021/acs.molpharmaceut.0c00087

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  4 in total

1.  Silencing of VEGFR2 by RGD-Modified Lipid Nanoparticles Enhanced the Efficacy of Anti-PD-1 Antibody by Accelerating Vascular Normalization and Infiltration of T Cells in Tumors.

Authors:  Riki Cho; Yu Sakurai; Haleigh Sakura Jones; Hidetaka Akita; Akihiro Hisaka; Hiroto Hatakeyama
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

2.  Cytosolic protein delivery using pH-responsive, charge-reversible lipid nanoparticles.

Authors:  Yusuke Hirai; Hisaaki Hirose; Miki Imanishi; Tomohiro Asai; Shiroh Futaki
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

3.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Farid Hashemi; Ebrahim Rahmani Moghadam; Mehdi Raei; Mahshad Kalantari; Shima Tavakol; Reza Mohammadinejad; Masoud Najafi; Franklin R Tay; Pooyan Makvandi
Journal:  ACS Comb Sci       Date:  2020-10-23       Impact factor: 3.784

Review 4.  New Applications of Lipid and Polymer-Based Nanoparticles for Nucleic Acids Delivery.

Authors:  Adelina-Gabriela Niculescu; Alexandra Cătălina Bîrcă; Alexandru Mihai Grumezescu
Journal:  Pharmaceutics       Date:  2021-12-01       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.